๐๐ฎ๐ฅ๐ฒ ๐๐๐ฐ๐ฌ ๐๐จ๐ฎ๐ง๐ ๐๐ฉ ๐ ๐๐๐ฎ๐ฌ๐๐ก & ๐๐จ๐ฆ๐ ๐๐๐ช๐ฎ๐ข๐ซ๐๐ฌ ๐๐ซ๐ฎ๐ค๐๐ซ๐...
๐๐ง๐ง๐จ๐ฏ๐๐ญ๐ข๐จ๐ง๐ฌ ๐ข๐ง ๐๐ซ๐ฒ ๐๐ฒ๐ ๐๐ก๐๐ซ๐๐ฉ๐ฒ: ๐๐๐ฐ ๐๐จ๐ฅ๐ฎ๐ญ๐ข๐จ๐ง๐ฌ ๐๐ซ๐จ๐ฆ ๐๐จ๐ซ๐๐ข๐ ๐๐ก๐๐ซ๐ฆ๐, ๐๐๐ฎ๐ฌ๐๐ก + ๐๐จ๐ฆ๐, ๐๐ง๐ ๐๐ข๐จ๐๐ข๐ฌ๐ฌ๐ฎ๐
๐ Nordic Pharma Launches Lacrifill Canicular Gel for Dry Eye Therapy in the US
Nordic Pharma is making waves in the US market with the introduction of its innovative dry eye therapy, the Lacrifill Canalicular Gel. This novel treatment is derived from cross-linked hyaluronic acid (HA) and is designed to temporarily block tear drainage by occluding the canalicular system. The launch of Lacrifill marks Nordic Pharmaโs second branded medical device to be made commercially available in the United States. According to Eric D. Donnenfeld, MD, chair of Nordic Pharmaโs US Medical Advisory Board, this device is a โdisruptive technology that will change how ophthalmologists practice.โ
๐ง Bausch + Lomb Unveils Blink Nutritears for Dry Eye Symptoms
Bausch + Lomb has announced the US launch of Blink Netritears, a groundbreaking over-the-counter supplement aimed at addressing the root causes of dry eyes. Blink nutritears promotes healthy tear production and provides relief from eye dryness symptoms within just 2 to 4 weeks. John Ferris, executive vice president of consumer at Bausch + Lomb, highlighted in a company news release that many consumers seek options beyond traditional eye drops. Blink nutritears stands out as a first-of-its-kind, clinically proven nutritional supplement that hydrates eyes from within, offering long-lasting relief and complementing the companyโs expanding dry eye portfolio.
๐ BioTissue Introduces CAM360 AmnioGraft Therapy for Dry Eye and Ocular Surface Disorders
BioTissue has launched CAM360 AmnioGraft (CAM360 AG), a new hydrated, shelf-stable Cryopreserved Amniotic Membrane (CAM) solution designed to treat dry eye and various ocular surface disorders. Ted Davies, President and CEO of BioTissue, stated in a company news release that CAM360 AG revolutionises the use of regenerative medicine in treating the ocular surface, particularly for dry eye disease. He emphasised that dry eye disease is progressive and that CA<360 AG enables practitioners to intervene earlier, providing more patients with timely treatment. This innovation reflects BioTissueโs commitment to enhancing patientsโ lives through cutting-edge medical solutions.
